Forbion

Dualyx specializes in the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company focuses on creating immune modulators, particularly Treg-targeted therapies, which are designed to suppress unwanted autoimmune reactions in patients. By advancing these innovative treatments, Dualyx aims to provide lasting solutions for individuals suffering from autoimmune diseases, ultimately enabling medical professionals to offer effective cures.

Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.

Armgo Pharma, Inc. is a biopharmaceutical company focused on developing small-molecule therapeutics for debilitating cardiac, skeletal muscular, and neurological disorders. The company specializes in calcium release channel stabilizers known as Rycals, which target the ryanodine receptor/calcium release channel located on the sarcoplasmic/endoplasmic reticulum of cells. These therapeutics are designed to address various conditions, including chronic heart failure, cardiac arrhythmias, muscle disorders, cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. Founded in 2004, Armgo Pharma is headquartered in Tarrytown, New York, with an additional office in New York City.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, established in 2017. The company specializes in the development and manufacturing of novel therapeutics aimed at addressing metabolic, inflammatory, and fibrotic diseases. It focuses on creating first-in-class, oral lipid therapeutics through its proprietary Structurally Engineered Fatty Acid (SEFA) technology. One of its key products, icosabutate, is a structurally engineered fatty acid designed to treat inflammatory and liver diseases. The SEFA technology enables the development of candidates that exhibit a range of biological effects, effectively targeting issues such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis across various models.

Anaveon AG is a biopharmaceutical company based in Bottmingen, Switzerland, founded in 2017. The company specializes in developing biologics that modulate cytokine functions, particularly focusing on next-generation IL-2 complexes. These complexes selectively enhance effector T cell functions, acting as effective immune adjuvants with a broad therapeutic window. Anaveon's innovative compounds demonstrate significant preclinical efficacy against cancer, both as standalone treatments and in combination with other therapies. The company's mission is to transform cytokines into life-saving treatments for patients suffering from various diseases characterized by immune system dysfunction. Through its targeted approach, Anaveon aims to provide substantial therapeutic benefits to cancer patients and others affected by immune pathology.

Prilenia Therapeutics B.V., a clinical stage biotech company, researches and develops products for movement disorders and neurodegenerative diseases affecting adults and children. It offers Pridopidine, an orally bioavailable small molecule investigational drug for huntington disease, amyotrophic lateral sclerosis, Parkinson’s disease levodopa induced dyskinesia, neurodegenerative eye disease, Parkinson’s disease, rett syndrome, fragile X, and Alzheimer’s disease. The company was founded in 2018 and is based in the Netherlands.

Rectify is developing disease-modifying precision therapies that restore ABC transporter function to address the underlying cause of serious genetic diseases. The company’s pipeline spans multiple therapeutic areas.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, established in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on treatments for conditions related to intense pruritus, particularly in patients undergoing targeted anti-cancer therapies. Its lead asset, orvepitant, is an oral NK-1 antagonist designed to alleviate this specific symptom. Additionally, NeRRe is advancing other candidates, including NT-814, a dual NK-1 and NK-3 antagonist, and NT-949, which is ready for Phase I trials. The company also has NT-432, a clinical candidate targeting NK-1 receptors. NeRRe Therapeutics aims to address unmet medical needs through its innovative therapeutic approaches.

Developer of a medical platform designed to bring novel therapies to patients worldwide. The company's platform combines the therapeutic potential of antibodies and gene therapy to facilitate scalable manufacturing processes to target specific cell types and sub-cellular compartments whilst evading the host immune response, enabling medical practitioners to overcome limitations and focus on disease areas of unmet medical needs.

Numab Therapeutics AG is a biotechnology company based in Wädenswil, Switzerland, founded in 2011. The company specializes in developing antibody-based therapeutics aimed at treating severe diseases, including cancer and chronic inflammation. Numab utilizes a unique plug-and-play platform that enhances the predictability of the drug discovery process, allowing for the efficient creation of multispecific biotherapeutics. Its research pipeline encompasses various therapeutic areas, including inflammatory bowel disease, immuno-oncology, autoimmunity, and inflammation.

Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system. Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.

Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, founded in 2017. The company specializes in targeted protein degradation technology, which is aimed at developing innovative cancer therapeutics. Amphista's approach leverages the body's natural processes to selectively degrade and eliminate proteins that contribute to disease progression. By advancing next-generation therapeutics, the company seeks to improve treatment efficacy and enhance patient outcomes across a range of diseases. Amphista's research focuses on identifying novel methods to modulate the cell's degradation machinery, thereby addressing the underlying mechanisms of various conditions.

Precision Ocular Metrology is a medical device startup dedicated to revolutionizing the way we measure ocular surface topography. Standard Placido disk slope measurements are great for optical power measurements on the central regions of the cornea but provide poor elevation topography, making them poor choices for specialty lens fitting. Our sMap3D topographer addresses this problem by providing direct anterior surface elevation measurements, letting you map the complete three-dimensional eye surface with an unprecedented 10 um precision.

CoviCept Therapeutics is focused on the development of a small molecule that inhibits the replication and spread of RNA viruses.

Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, specializes in the development of immuno-oncology therapeutics. The company focuses on creating antibodies that target a placental factor known to be overexpressed in various tumor types. Through its innovative approach, CatalYm aims to enhance cancer treatment options and improve patient outcomes in the field of oncology.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists. Founded in 2015, the company aims to address various health conditions, including Prader-Willi syndrome, Type-1 diabetes, obesity, and other metabolic disorders such as non-alcoholic steatohepatitis. Inversago's approach seeks to overcome limitations associated with earlier generations of CB1 blockers, thereby maximizing their therapeutic potential. By advancing new drug candidates, Inversago Pharma is positioned to provide healthcare professionals and patients with effective treatment options for metabolic and fibrotic disorders.

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.

Prilenia Therapeutics B.V., a clinical stage biotech company, researches and develops products for movement disorders and neurodegenerative diseases affecting adults and children. It offers Pridopidine, an orally bioavailable small molecule investigational drug for huntington disease, amyotrophic lateral sclerosis, Parkinson’s disease levodopa induced dyskinesia, neurodegenerative eye disease, Parkinson’s disease, rett syndrome, fragile X, and Alzheimer’s disease. The company was founded in 2018 and is based in the Netherlands.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Azafaros B.V. is a Netherlands-based company focused on developing therapeutic agents for the treatment of rare metabolic disorders, specifically lysosomal storage disorders (LSDs). The company specializes in the oral administration of aza-sugar compounds, which were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. These innovative agents aim to address key disease pathways by targeting the metabolism of glycosphingolipids and are designed to have a dual mode of action that can potentially improve patient outcomes. Through its research and development efforts, Azafaros seeks to provide effective treatments that can significantly enhance the lives of those affected by these severe inherited diseases.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, established in 2017. The company specializes in the development and manufacturing of novel therapeutics aimed at addressing metabolic, inflammatory, and fibrotic diseases. It focuses on creating first-in-class, oral lipid therapeutics through its proprietary Structurally Engineered Fatty Acid (SEFA) technology. One of its key products, icosabutate, is a structurally engineered fatty acid designed to treat inflammatory and liver diseases. The SEFA technology enables the development of candidates that exhibit a range of biological effects, effectively targeting issues such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis across various models.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.

Inflazome Ltd. is a biotechnology company based in Dublin, Ireland, founded in 2016, that focuses on developing orally available drugs for inflammatory diseases by targeting the inflammasome. The company's innovative approach aims to block inflammasome signals, addressing the underlying causes of inflammation. Inflazome's portfolio includes treatments for a range of conditions, such as orphan diseases like Muckle-Wells syndrome and familial cold autoinflammatory syndrome, as well as chronic inflammatory disorders affecting the central nervous system, including Alzheimer's, Parkinson's, and multiple sclerosis. The company also targets systemic inflammatory diseases like cardiovascular and gastrointestinal issues, and explores applications in oncology and dermatology. Inflazome operates as a subsidiary of Roche Holding AG.

OMEICOS Therapeutics GmbH is a biotechnology company focused on developing innovative therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases. Established in 2013 and headquartered in Berlin, Germany, the company is pioneering a first-in-class small molecule that leverages a unique mode of action based on natural metabolites of omega-3 fatty acids. These metabolites exhibit strong anti-arrhythmic properties by activating an endogenous cardio-protective signaling pathway, which not only stabilizes heart rhythm but also aims to provide curative effects by preventing electrical and structural remodeling of the heart. OMEICOS' approach is designed to offer safe and effective treatment options for patients with cardiovascular conditions, while also addressing inflammatory diseases and other indications.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on the development and commercialization of etripamil, a novel calcium channel blocker targeting various cardiovascular conditions. Etripamil is designed as a rapid-onset nasal spray for the self-administration by patients, specifically to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently advancing etripamil through Phase III clinical trials for PSVT in the United States and Canada, as well as conducting Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003, Milestone aims to address unmet medical needs in the treatment of transient cardiovascular conditions, including atrial fibrillation and angina.

Gotham Therapeutics is a biotechnology company based in New York that focuses on developing a novel class of drugs aimed at targeting epitranscriptomics machinery. Established in 2017, the company seeks to create new treatment options for patients afflicted with various conditions, including cancers, autoimmune disorders, and neurodegenerative diseases. By altering the activity of proteins that modify messenger ribonucleic acid (mRNA), Gotham Therapeutics aims to advance therapeutic strategies and improve patient outcomes in these challenging medical areas.

KANDY THERAPEUTICS LIMITED develops non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening. The company offers NT-814, a drug for common, chronic debilitating female sex-hormone related treatment. It provides non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment, and reduce symptoms of hormone related conditions. The company was founded in 2017 and is based in Stevenage, United Kingdom. KANDY THERAPEUTICS LIMITED operates as a subsidiary of Bayer Aktiengesellschaft.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Escalier Biosciences BV is a privately held biopharmaceutical company developing novel small molecule therapeutics that target ROR?t for the treatment of psoriasis and other autoimmune disorders. Escalier's lead topical and oral drug candidates are currently in late stage preclinical studies. Escalier is registered in The Netherlands with offices in Nijmegen, The Netherlands and Encinitas, California.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, established in 2017. The company specializes in the development and manufacturing of novel therapeutics aimed at addressing metabolic, inflammatory, and fibrotic diseases. It focuses on creating first-in-class, oral lipid therapeutics through its proprietary Structurally Engineered Fatty Acid (SEFA) technology. One of its key products, icosabutate, is a structurally engineered fatty acid designed to treat inflammatory and liver diseases. The SEFA technology enables the development of candidates that exhibit a range of biological effects, effectively targeting issues such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis across various models.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on the development and commercialization of etripamil, a novel calcium channel blocker targeting various cardiovascular conditions. Etripamil is designed as a rapid-onset nasal spray for the self-administration by patients, specifically to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently advancing etripamil through Phase III clinical trials for PSVT in the United States and Canada, as well as conducting Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003, Milestone aims to address unmet medical needs in the treatment of transient cardiovascular conditions, including atrial fibrillation and angina.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Prexton Therapeutics is a Swiss-based biopharmaceutical company, founded in 2012 by Francois Conquet and MS Ventures as part of the Merck Serono Entrepreneur Partnership Program, a facility to support the creation of spin-offs from Merck Serono. Prexton Therapeutics applies a new scientific approach that fully integrates molecular, behavioural and chemistry technologies to address Parkinson’s disease and other brain disorders. Prexton Therapeutics uses its powerful discovery platform to target specific novel compounds focused on the treatment of Parkinson’s disease.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, established in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on treatments for conditions related to intense pruritus, particularly in patients undergoing targeted anti-cancer therapies. Its lead asset, orvepitant, is an oral NK-1 antagonist designed to alleviate this specific symptom. Additionally, NeRRe is advancing other candidates, including NT-814, a dual NK-1 and NK-3 antagonist, and NT-949, which is ready for Phase I trials. The company also has NT-432, a clinical candidate targeting NK-1 receptors. NeRRe Therapeutics aims to address unmet medical needs through its innovative therapeutic approaches.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.

Rigontec GmbH is a biopharmaceutical company specializing in RNA-based immunotherapeutics aimed at treating cancer and viral diseases. Founded in 2014 and based in Planegg, Germany, the company focuses on developing compounds that activate the immune receptor retinoic acid-inducible gene I (RIG-I), specifically through its lead product, ImOl100. This compound acts as a minimal mimic of the naturally occurring 3pRNA motif found in viral RNAs, stimulating the immune response effectively. Rigontec's approach circumvents common challenges faced by traditional cancer therapies, such as vaccines and checkpoint inhibitors, by targeting RIG-I pathways to induce tumor cell death and promote long-term immunity. In 2017, Rigontec became a subsidiary of Merck & Co., Inc., enhancing its capabilities in the field of immuno-oncology.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, specializes in the development of immuno-oncology therapeutics. The company focuses on creating antibodies that target a placental factor known to be overexpressed in various tumor types. Through its innovative approach, CatalYm aims to enhance cancer treatment options and improve patient outcomes in the field of oncology.

Allecra Therapeutics GmbH, founded in 2013 and based in Weil am Rhein, Germany, focuses on developing innovative pharmaceuticals to address gram-negative multi-drug-resistant bacterial infections. The company is currently advancing a novel β-lactamase inhibitor through Phase 2 clinical development. This new treatment aims to counteract the resistance mechanisms of difficult-to-treat bacteria, which are particularly prevalent in hospital-acquired infections. By inhibiting β-lactamases, Allecra's approach directly targets the challenges posed by these resistant strains, providing healthcare providers with effective options to manage infections that may otherwise be inadequately treated. Situated in the BioValley Life Sciences region, Allecra Therapeutics is committed to delivering solutions that can save lives and improve patient outcomes in the face of rising antibiotic resistance.

Akarna Therapeutics Ltd. is a biopharmaceutical company focused on developing small molecule therapeutics aimed at treating inflammatory and fibrotic diseases. Headquartered in Cambridge, United Kingdom, with an additional office in San Diego, California, the company has been working on a lead program involving a non-bile acid FXR agonist. This therapeutic candidate targets nonalcoholic steatohepatitis (NASH), a progressive fatty-liver disease for which there are currently no approved treatment options. As of August 2016, Akarna operates as a subsidiary of Allergan plc. The lead candidate is in the preclinical phase, undergoing toxicology and safety pharmacology studies, with plans for first-in-human trials in the near future.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Autonomic Technologies, Inc. is a medical device company that focuses on the development and commercialization of therapies for the treatment of autonomic disorders, particularly severe headache. It develops ATI Neurostimulation System, a device that delivers low-level energy directly to the area of the SPG for the treatment of chronic cluster headache. The company was founded in 2007 and is based in Mountain View, California with additional offices in Germany and Switzerland.

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Rigontec GmbH is a biopharmaceutical company specializing in RNA-based immunotherapeutics aimed at treating cancer and viral diseases. Founded in 2014 and based in Planegg, Germany, the company focuses on developing compounds that activate the immune receptor retinoic acid-inducible gene I (RIG-I), specifically through its lead product, ImOl100. This compound acts as a minimal mimic of the naturally occurring 3pRNA motif found in viral RNAs, stimulating the immune response effectively. Rigontec's approach circumvents common challenges faced by traditional cancer therapies, such as vaccines and checkpoint inhibitors, by targeting RIG-I pathways to induce tumor cell death and promote long-term immunity. In 2017, Rigontec became a subsidiary of Merck & Co., Inc., enhancing its capabilities in the field of immuno-oncology.

Insmed Incorporated is a biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. Based in Bridgewater, New Jersey, the company’s primary product is ARIKAYCE, an inhalation suspension approved in the United States for treating Mycobacterium avium complex lung disease, specifically for adult patients who have limited or no alternative treatment options. In addition to ARIKAYCE, Insmed is advancing its clinical pipeline with INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 aimed at treating non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug designed for rare pulmonary disorders, including pulmonary arterial hypertension. Founded in 1988, Insmed continues to focus on providing innovative solutions for unmet medical needs in challenging therapeutic areas.

enGene, Inc. is a biotechnology company specializing in mucosal immunotherapy platforms aimed at treating inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables localized delivery of immune-modulating proteins to mucosal tissues, including the gastrointestinal tract, lung, and bladder. This innovative approach allows for the treatment of various immune disorders and supports systemic release of proteins from the gut to address conditions such as diabetes, anemia, and hemophilia. Founded in 1999 and based in Vancouver, Canada, enGene has formed a strategic alliance with Takeda Pharmaceutical Company Ltd. The company's platform facilitates the induction or suppression of protein expression levels, which can help regenerate physiologic, meal-regulated insulin secretion for diabetes patients.

Curetis N.V. is a commercial-stage molecular diagnostics company based in Holzgerlingen, Germany, specializing in solutions for severe infectious diseases. The company develops and manufactures a range of molecular microbiology products aimed at detecting various pathogens, including bacteria and fungi, as well as identifying genetic markers for antimicrobial resistance. Key offerings include the Unyvero L4 Lysator for sample pre-processing, the Unyvero A50 Analyzer, and the Unyvero C8 Cockpit, which serves as a control panel for these devices. Curetis also provides Unyvero Application Cartridges for syndromic infectious disease testing and the ARES AMR Database, which compiles data on antimicrobial resistance genetics. Its tests cover multiple infections, including pneumonia and urinary tract infections. Founded in 2007, Curetis has established strategic partnerships with companies like MGI Tech Co. Ltd. and Qiagen N.V., enhancing its capabilities in the molecular diagnostics market.

Pulmologix AB is a Swedish private clinical stage company focused on developing, manufacturing, and selling an oral non-steroidal anti-asthmatic drug designed for the treatment of early onset allergic asthma. Established in 2006 and headquartered in Stockholm, the company aims to address unmet medical needs in asthma management through its innovative therapeutic approach.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Ario Pharma ltd focusses on the development of drugs for the treatment of respiratory indications. Ario is about to evaluate the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, in two Phase 2 clinical trials that will read out in 2014. The company is managed by a highly experienced development team and supported by world-renowned KOLs in respiratory disease.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Allecra Therapeutics GmbH, founded in 2013 and based in Weil am Rhein, Germany, focuses on developing innovative pharmaceuticals to address gram-negative multi-drug-resistant bacterial infections. The company is currently advancing a novel β-lactamase inhibitor through Phase 2 clinical development. This new treatment aims to counteract the resistance mechanisms of difficult-to-treat bacteria, which are particularly prevalent in hospital-acquired infections. By inhibiting β-lactamases, Allecra's approach directly targets the challenges posed by these resistant strains, providing healthcare providers with effective options to manage infections that may otherwise be inadequately treated. Situated in the BioValley Life Sciences region, Allecra Therapeutics is committed to delivering solutions that can save lives and improve patient outcomes in the face of rising antibiotic resistance.

Dezima Pharma B.V., founded in 2012 and based in Naarden, the Netherlands, focuses on developing protein-based compounds for the treatment of cardiovascular diseases associated with dyslipidemia. The company specializes in creating novel drugs, including a cholesteryl ester transfer protein inhibitor, aimed at lowering low-density lipoprotein cholesterol levels. By addressing these lipid imbalances, Dezima Pharma provides clinicians with pharmacological therapies that can effectively treat patients suffering from dyslipidemic-related cardiovascular conditions.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.

Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company is engaged in researching and commercializing therapies that aim to genetically modify patients' cells to correct the underlying genetic causes of diseases. Key programs include LentiGlobin for β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing CAR T cell therapies, such as bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with Bristol-Myers Squibb and Regeneron Pharmaceuticals to advance gene therapies in oncology, and works with various partners to develop innovative solutions in cancer treatment and in vivo genome editing for genetic disorders. Founded in 1992 and headquartered in Cambridge, Massachusetts, bluebird bio generates revenue through collaboration arrangements, research fees, license fees, and grants.

Santaris Pharma A/S is a clinical-stage biopharmaceutical company specializing in RNA-targeted therapies. Founded in 2003 and headquartered in Denmark, the company utilizes its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine to develop single-stranded LNA-based drug candidates for various diseases. Its research focuses on infectious diseases and cardiometabolic disorders, while also addressing cancer, cardiovascular diseases, inflammatory diseases, and rare genetic disorders through collaborations with major pharmaceutical firms. Santaris Pharma has established partnerships with organizations such as miRagen Therapeutics, Shire, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. The company holds exclusive worldwide rights to manufacture and sell products containing LNA as an active ingredient, which supports its goal of obtaining marketing approval for its innovative therapies.

Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps for long-term partial circulatory support. The company’s proprietary micro-pump platform allows for the creation of small devices that can be implanted in a manner similar to a pacemaker, using endovascular or minimally-invasive surgical techniques. By supplementing a patient's natural heart function, CircuLite's devices aim to provide a proactive and lower-risk treatment option, potentially enhancing the quality of life for millions of individuals suffering from chronic heart failure and their families.

Oxyrane UK Limited, a biopharmaceutical company, develops novel and biosuperior enzyme replacement therapies for the treatment of lysosomal storage diseases. It provides human lysosomal enzymes that enable clinically effective enzyme uptake and localization using its glycoengineered yeast platform. The company was founded in 2006 and is based in Manchester, United Kingdom. It has locations in Gent, Belgium; and Burlington, Massachusetts.

Curetis N.V. is a commercial-stage molecular diagnostics company based in Holzgerlingen, Germany, specializing in solutions for severe infectious diseases. The company develops and manufactures a range of molecular microbiology products aimed at detecting various pathogens, including bacteria and fungi, as well as identifying genetic markers for antimicrobial resistance. Key offerings include the Unyvero L4 Lysator for sample pre-processing, the Unyvero A50 Analyzer, and the Unyvero C8 Cockpit, which serves as a control panel for these devices. Curetis also provides Unyvero Application Cartridges for syndromic infectious disease testing and the ARES AMR Database, which compiles data on antimicrobial resistance genetics. Its tests cover multiple infections, including pneumonia and urinary tract infections. Founded in 2007, Curetis has established strategic partnerships with companies like MGI Tech Co. Ltd. and Qiagen N.V., enhancing its capabilities in the molecular diagnostics market.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.

Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique ‘Localized Drug Action' platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.

gIcare Pharma Inc. is a biopharmaceutical start-up established in 2011 and based in Montreal, Canada, specializing in the development of innovative gastrointestinal drugs. The company focuses on addressing unmet medical needs in the field of gastroenterology, aiming to create medicines that not only benefit patients but also offer clinical advantages to healthcare providers and economic benefits to payers. gIcare's flagship drug candidate, GIC-1001, exemplifies this approach by integrating multiple levels of benefits, reflecting the company's commitment to advancing healthcare solutions in gastrointestinal medicine.

Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company is engaged in researching and commercializing therapies that aim to genetically modify patients' cells to correct the underlying genetic causes of diseases. Key programs include LentiGlobin for β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing CAR T cell therapies, such as bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with Bristol-Myers Squibb and Regeneron Pharmaceuticals to advance gene therapies in oncology, and works with various partners to develop innovative solutions in cancer treatment and in vivo genome editing for genetic disorders. Founded in 1992 and headquartered in Cambridge, Massachusetts, bluebird bio generates revenue through collaboration arrangements, research fees, license fees, and grants.

They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need to manage their condition. The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes.

PneumRx, Inc. is a medical device company that specializes in developing minimally invasive treatments for patients with emphysema. Founded in 2004 and headquartered in Mountain View, California, the company is known for its RePneu Lung Volume Reduction Coil, an investigational device aimed at improving the quality of life for individuals suffering from this chronic respiratory condition. PneumRx focuses on addressing unmet medical needs in pulmonary medicine through innovative solutions.

Cardoz AB manufactures anti-inflammatory pharmaceuticals to combat heart and vascular disorders. The company was founded in 2006 and is based in Stockholm, Sweden.

Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.

Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company is engaged in researching and commercializing therapies that aim to genetically modify patients' cells to correct the underlying genetic causes of diseases. Key programs include LentiGlobin for β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing CAR T cell therapies, such as bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with Bristol-Myers Squibb and Regeneron Pharmaceuticals to advance gene therapies in oncology, and works with various partners to develop innovative solutions in cancer treatment and in vivo genome editing for genetic disorders. Founded in 1992 and headquartered in Cambridge, Massachusetts, bluebird bio generates revenue through collaboration arrangements, research fees, license fees, and grants.

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps for long-term partial circulatory support. The company’s proprietary micro-pump platform allows for the creation of small devices that can be implanted in a manner similar to a pacemaker, using endovascular or minimally-invasive surgical techniques. By supplementing a patient's natural heart function, CircuLite's devices aim to provide a proactive and lower-risk treatment option, potentially enhancing the quality of life for millions of individuals suffering from chronic heart failure and their families.

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

novoGI™ (previously NiTi Surgical Solutions) is committed to advancing patient care by providing an expanding range of comprehensive solutions for GI disease management. NiTi Surgical Solutions has developed the first major advance in closure for gastrointestinal surgery in more than 30 years. NiTi's proprietary technology represents a breakthrough in natural healing with tissue-sparing, uniform BioDynamix anastomosis. The company's unique line of products utilizes Nitinol-based elements to press together the ends of resected tissue, enabling a natural reconnection of the intestine after removing a section, for example, as part of a colon cancer treatment. The company is commercializing a family of FDA-cleared and CE-marked disposable tissue closure devices.

Pathway Medical Technologies Inc. designs, develops, manufactures, and markets medical devices for the treatment of arterial and vascular diseases.

Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

PanGenetics B.V., based in Utrecht, Netherlands, specializes in the development of monoclonal antibodies aimed at treating immune-mediated diseases. The company focuses on advancing antibodies from late-stage research to clinical proof of concept, utilizing a lean business model that outsources manufacturing and clinical development to specialized providers. Among its clinical programs is PG110, along with PG102, a CD40 antagonist currently undergoing evaluation in a clinical study for patients with psoriatic arthritis. Additionally, PanGenetics employs an in-licensing model to expand its portfolio of antibody-based therapeutic products. The company's strategic approach allows it to concentrate on its core competencies while leveraging external expertise for other critical functions.

Santaris Pharma A/S is a clinical-stage biopharmaceutical company specializing in RNA-targeted therapies. Founded in 2003 and headquartered in Denmark, the company utilizes its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine to develop single-stranded LNA-based drug candidates for various diseases. Its research focuses on infectious diseases and cardiometabolic disorders, while also addressing cancer, cardiovascular diseases, inflammatory diseases, and rare genetic disorders through collaborations with major pharmaceutical firms. Santaris Pharma has established partnerships with organizations such as miRagen Therapeutics, Shire, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. The company holds exclusive worldwide rights to manufacture and sell products containing LNA as an active ingredient, which supports its goal of obtaining marketing approval for its innovative therapies.

Fovea Pharmaceuticals is a French biopharmaceutical company based in Paris, specializing in the discovery and development of drugs for ocular diseases. Founded in 2005, the company focuses on addressing various eye conditions, including allergic conjunctivitis, diabetic macular edema, and retinitis pigmentosa. Its product portfolio includes FOV1101 Prednisporin for allergic conjunctivitis, a proprietary plasma kallikrein-kinin inhibitor known as FOV2302 for hereditary angioedema, FOV2304 for diabetic macular edema, and FOV2501, an intravitreal formulation targeting retinitis pigmentosa and potentially dry age-related macular degeneration. As of October 30, 2009, Fovea operates as a subsidiary of Sanofi.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps for long-term partial circulatory support. The company’s proprietary micro-pump platform allows for the creation of small devices that can be implanted in a manner similar to a pacemaker, using endovascular or minimally-invasive surgical techniques. By supplementing a patient's natural heart function, CircuLite's devices aim to provide a proactive and lower-risk treatment option, potentially enhancing the quality of life for millions of individuals suffering from chronic heart failure and their families.